Lol, I don’t like to purely speculate (which thi
Post# of 155585
(Total Views: 335)
Posted On: 04/10/2019 9:20:03 PM
Lol, I don’t like to purely speculate (which this is) and others may have some other thoughts, but here are a few that I can think of:
- License deal/s (whether PCa, HIV, GvHD, etc.....one would think they would wait until after such deal is announced, but that wasn’t the case with the raises and in all honesty there would be a lot of work put into such deal before it is official or compete....and any employee would prefer stock options at lower cost which would be likely before any such deal is announced).
- Employee incentive/s (could be a huge selling point to bring in the right person as the commercialization director and building team.....or possible management shake up.
Again all speculation, but I truly believe there will be some positive news coming our way and if cancer results are positive (which I believe they will be and was reading some non-Pestell articles about CCR5 stopping cancer metastasis earlier today) I am not worried about 100M increase in shares. The cancer market is enormous....estimates are 1.7M diagnosed in US in 2019 and if leronlimab works this will potentially address roughly 50% of this market in which CCR5 is expressed.
- License deal/s (whether PCa, HIV, GvHD, etc.....one would think they would wait until after such deal is announced, but that wasn’t the case with the raises and in all honesty there would be a lot of work put into such deal before it is official or compete....and any employee would prefer stock options at lower cost which would be likely before any such deal is announced).
- Employee incentive/s (could be a huge selling point to bring in the right person as the commercialization director and building team.....or possible management shake up.
Again all speculation, but I truly believe there will be some positive news coming our way and if cancer results are positive (which I believe they will be and was reading some non-Pestell articles about CCR5 stopping cancer metastasis earlier today) I am not worried about 100M increase in shares. The cancer market is enormous....estimates are 1.7M diagnosed in US in 2019 and if leronlimab works this will potentially address roughly 50% of this market in which CCR5 is expressed.
(0)
(0)CytoDyn Inc (CYDY) Stock Research Links
Please do your own due diligence. All my posts and comments are not to be considered investment advice.